FOUNDED IN 2010

Dramatic advances in the biotechnology sector are creating an unprecedented opportunity to translate scientific breakthroughs into transformative medicines. Aquilo Capital invests in drug development companies that harness the power of cutting-edge science to address urgent medical needs. We employ deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. In our view, these investment opportunities offer both substantial risk-adjusted returns as well as paradigm-changing therapeutics for patients and for society.

OUR TEAM

Marc Schneidman

CHIEF INVESTMENT OFFICER

Adam Bristol, PhD

DIRECTOR OF RESEARCH

Cariad Chester

PRINCIPAL